Rapamycin Increases Mortality in db/db Mice, a Mouse Model of Type 2 Diabetes

J Gerontol A Biol Sci Med Sci. 2016 Jul;71(7):850-7. doi: 10.1093/gerona/glv170. Epub 2015 Oct 5.

Abstract

We examined the effect of rapamycin on the life span of a mouse model of type 2 diabetes, db/db mice. At 4 months of age, male and female C57BLKSJ-lepr (db/db) mice (db/db) were placed on either a control diet, lacking rapamycin or a diet containing rapamycin and maintained on these diets over their life span. Rapamycin was found to reduce the life span of the db/db mice. The median survival of male db/db mice fed the control and rapamycin diets was 349 and 302 days, respectively, and the median survival of female db/db mice fed the control and rapamycin diets was 487 and 411 days, respectively. Adjusting for gender differences, rapamycin increased the mortality risk 1.7-fold in both male and female db/db mice. End-of-life pathological data showed that suppurative inflammation was the main cause of death in the db/db mice, which is enhanced slightly by rapamycin treatment.

Keywords: Life span; Obesity; Toxicity; mTOR Inhibition.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Cause of Death
  • Diabetes Mellitus, Experimental* / metabolism
  • Diabetes Mellitus, Experimental* / mortality
  • Diabetes Mellitus, Experimental* / pathology
  • Diabetes Mellitus, Experimental* / physiopathology
  • Diabetes Mellitus, Type 2* / metabolism
  • Diabetes Mellitus, Type 2* / mortality
  • Diabetes Mellitus, Type 2* / pathology
  • Diabetes Mellitus, Type 2* / physiopathology
  • Female
  • Immunosuppressive Agents / metabolism
  • Immunosuppressive Agents / pharmacology
  • Inflammation / pathology*
  • Longevity* / drug effects
  • Longevity* / physiology
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mortality
  • Sex Factors
  • Sirolimus* / metabolism
  • Sirolimus* / pharmacology
  • Treatment Outcome

Substances

  • Immunosuppressive Agents
  • Sirolimus